Related Experiment Video
Updated: Sep 20, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Evolution of Antiviral Drug Resistance in SARS-CoV-2
Roy Dinata1, Piyush Baindara1, Santi M Mandal2
1Animal Science Research Center, Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA.
Abstract:
The COVID-19 pandemic has had a significant impact and continues to alarm the entire world due to the rapid emergence of new variants, even after mass vaccinations. There is still an urgent need for new antivirals or strategies to combat the SARS-CoV-2 infections; however, we have success stories with nirmatrelvir. Drug repurposing and drug discovery may lead to a successful SARS-CoV-2 antiviral; however, rapid drug use may cause unexpected mutations and antiviral drug resistance. Conversely, novel variants of the SARS-CoV-2 can diminish the neutralizing efficacy of vaccines, thereby enhancing viral fitness and increasing the likelihood of drug resistance emergence. Additionally, the disposal of antivirals in wastewater also contributes to drug resistance. Overall, the present review summarizes the strategies and mechanisms involved in the development of drug resistance in SARS-CoV-2. Understanding the mechanism of antiviral resistance is crucial to mitigate the significant healthcare threat and to develop effective therapeutics against drug resistance.
Related Concept Videos
Viral Mutations
Retrovirus Life Cycles
Development of Antibiotic Resistance
Treatment Resistant Cancers
Single Nucleotide Polymorphisms-SNPs
The Antiviral System of Bacteria and Archaea: CRISPR

